The project is estimated to run from late Q4 2023 until Q1 2026 and the platform is aimed to shorten time for drug development workflows. The project will run in a ramp-up phase during 2024 and the vast majority of the project will be carried out and invoiced during 2025.
“This agreement is a milestone for the Group and it’s our largest project to date. It also shows the strength in Biosero’s offering for laboratory automation solutions and we expect to shorten current timelines for drug development through automation”, says Maria Forss, President and CEO, BICO.
BICO company Biosero signs agreement to develop laboratory automation solutions to a value of 28 MUSD
Biosero, a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, has signed an agreement with a global life science company for a total value of 28 MUSD to design and build an automated R&D, hardware and software platform which consists of 5 sub-projects
You may also like
Research & Development
Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme
Read morePoolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Trending Articles
You may also like
Research & Development
Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme
Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Research & Development
Lilly’s Jaypirca outperforms Imbruvica in landmark Phase III CLL trial, showing higher response rates and strong PFS trend
Pirtobrutinib met its primary endpoint and delivered higher overall response rates than ibrutinib in the BRUIN CLL-314 study, with early progression-free survival data also favouring Lilly’s next-generation BTK inhibitor
Research & Development
Global myalgic encephalomyelitis study identifies 250+ core genes and shared biology with long COVID
PrecisionLife’s large-scale genomic analysis reveals major biological drivers of ME and its overlap with long COVID, identifying dozens of drug repurposing opportunities and paving the way for more targeted clinical trials
Research & Development
Servier and University College London partner to advance research in rare genetic epileptic disorders
Servier will collaborate with UCL to evaluate antisense oligonucleotide candidates in cutting-edge brain assembloid models, aiming to accelerate therapeutic advances for patients with developmental and epileptic encephalopathy (DEE)
Research & Development
EU chemicals reforms rarely reflected in pharmaceutical policy, new study finds
A new analysis shows major EU Green Deal-driven chemicals legislation changes are seldom integrated into pharmaceutical policy, highlighting the need for closer alignment between health and environmental regulation